Physician profile
Christopher L White
NPI 1316987639
$4,136.27
in general payments reported to CMS, 2019-2025
28 companies · $1,308 in 2025
The $1,308 reported for 2025 was more than what 94% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $250 · 2020: $216 · 2021: $352 · 2022: $458 · 2023: $1,028 · 2024: $523 · 2025: $1,308.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,634 · Education: $225.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,634.22 |
| Education | $225.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $553.24 | 2021-2025 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $504.47 | 2019-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Abbvie INC. | $389.33 | 2021-2025 | Vraylar |
| Livanova USA, INC. | $346.75 | 2024-2025 | Vns Therapy Symmetry Model 8103 Generator |
| E.R. Squibb & Sons, L.L.C. | $341.95 | 2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $296.41 | 2023-2025 | Austedo Xr, Austedo Xr, Austedo |
| Indivior INC. | $295.56 | 2022-2025 | Sublocade, Perseris |
| Allergan, INC. | $246.28 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $230.99 | 2020-2025 | Rexulti, Abilify Asimtufii |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $152.75 | 2023-2025 | Xifaxan |
| Neurocrine Biosciences, INC. | $104.27 | 2021-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $76.90 | 2021-2022 | |
| Tris Pharma INC | $70.38 | 2023-2024 | Dyanavel Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $63.69 | 2021-2024 | Trintellix |
| Idorsia Pharmaceuticals US INC | $61.13 | 2022-2023 | Quviviq |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $55.33 | 2021-2025 | Aplenzin |
| Novo Nordisk INC | $45.78 | 2025 | Ozempic, Rybelsus |
| Adlon Therapeutics L.P. | $41.05 | 2019-2021 | |
| Corium, LLC | $38.04 | 2025 | Azstarys |
| Sun Pharmaceutical Industries INC. | $32.61 | 2025 | |
| Supernus Pharmaceuticals, INC. | $31.06 | 2022-2023 | Qelbree |
| Lundbeck LLC | $29.65 | 2020 | |
| Noven Therapeutics, LLC | $28.38 | 2024 | Xelstrym, Secuado |
| Neos Therapeutics, LP | $26.65 | 2019 | |
| Eisai INC. | $19.44 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.34 | 2025 | |
| Vyera Pharmaceuticals, LLC | $18.98 | 2019 | |
| Vanda Pharmaceuticals INC. | $15.86 | 2023 | Fanapt, Hetlioz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.